Segment disclosures

Company overview

AKEBIA THERAPEUTICS, INC.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

1 dimension combinations 18 retained observations 12 reported periods

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Reportable Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=akba:ReportableSegmentMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3036903000 USD20261105Open filing evidence
2026-01-01 – 2026-09-30139575000 USD20261105Open filing evidence
2026-04-01 – 2026-06-3049128000 USD20260805Open filing evidence
2026-01-01 – 2026-06-30102672000 USD20260805Open filing evidence
2026-01-01 – 2026-03-3153544000 USD20260507Open filing evidence
2025-01-01 – 2025-12-31236196000 USD20260226Open filing evidence
2025-07-01 – 2025-09-3058766000 USD20261105Open filing evidence
2025-01-01 – 2025-09-30178574000 USD20261105Open filing evidence
2025-04-01 – 2025-06-3062472000 USD20260805Open filing evidence
2025-01-01 – 2025-06-30119808000 USD20260805Open filing evidence
2025-01-01 – 2025-03-3157336000 USD20260507Open filing evidence
2024-01-01 – 2024-12-31160180000 USD20260226Open filing evidence
2024-07-01 – 2024-09-3037428000 USD20251110Open filing evidence
2024-01-01 – 2024-09-30113683000 USD20251110Open filing evidence
2024-04-01 – 2024-06-3043648000 USD20250807Open filing evidence
2024-01-01 – 2024-06-3076255000 USD20250807Open filing evidence
2024-01-01 – 2024-03-3132607000 USD20250508Open filing evidence
2023-01-01 – 2023-12-31194623000 USD20260226Open filing evidence